Pharmaco - Today Stories

$44 million facility increases production of single-use bioprocess containers that are critical to the development of new vaccines and therapies OGDEN, Utah, April 20, 2022 - Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19. The Ogden site…

Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus (RSV) infections and prevent illness through vaccination Expands Pfizer’s innovative anti-infective pipeline and utilizes the company’s R&D, manufacturing and commercialization expertise with the goal of addressing a significant unmet need for RSV treatments NEW YORK & LONDON & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, dev…

Award Celebrates Outstanding Research With a Focus in 2022 on Gastroenterology Winners’ Discoveries Reveal the Power of the Gut Microbiome Recipients Receive Unrestricted $200,000 USD Award OSAKA, Japan, and CAMBRIDGE, Massachusetts, April 5, 2022 –  Takeda (TSE:4502/NYSE:TAK) and the New York Academy of Sciences today announced the winners of the fourth Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in gastroenterology. Each winner receives an unrestricted prize of $200,000 USD. The 2022 Senior Scientist Award winner is Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology and Dr. Robert J. Glaser Distinguished University Professor at Washingt…

Paris, April 4, 2022. Sanofi launches today its Diversity, Equity & Inclusion (DE&I) Board, the first-of-its-kind in the pharmaceutical industry to feature outside advisors. Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand. Sanofi’s DE&I strategy was revamped in June 2021 with set objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can bring their whole selves and engaging with the company’s diverse communities. The DE&I Boar…

Ion Torrent Genexus Dx Integrated Sequencer enables rapid NGS for diagnostic applications and clinical research CARLSBAD, Calif., (March 29, 2022) -- Thermo Fisher Scientific today launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in as little as a single day. Designed for use in clinical laboratories, the fully validated system enables users to perform both diagnostic testing and clinical research on a single instrument. “Next-generation sequencing has become an essential tool to bring the promise of precision medicine therapies to patients. With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital – including regional and community hospitals – can bring NGS in-house, gi…

* Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets * Collaboration to create, develop, manufacture and commercialize new class of potential therapeutics combining the superior features of multi-valent IgM antibodies over conventional IgG antibodies for stimulating cell surface receptors * IGM to receive $150 million upfront payments, potentially over $6 billion in aggregate development, regulatory and commercial milestones Paris, March 29, 2022 – Sanofi (NASDAQ: SNY) and IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology t…

Establishment of the first end-to-end Australian capability for product development and commercial scale production of mRNA, DNA and recombinant vaccines  By bringing together the technology, product development, GMP manufacturing, clinical and regulatory expertise of key consortium partners Technovalia, Sypharma and BioNet, Genetis will provide a unique Australian-based vaccine contract and product development manufacturing hub for Australian and offshore research organisations seeking access to quality capability and TGA approved products.  The founding partners have been sharing common interest and commitment in the fight against the COVID-19 pandemic through the rapid development, production and/or evaluation of several COVID vaccines. BioNet has established a strong DNA and mRNA manuf…

Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs LONDON, March 25, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals ("GW") – a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines – today announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne. The new state-of-the-art facility will be approximately…

SUZHOU, China, March 22, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has established a global clinical collaboration with Bristol Myers Squibb to evaluate the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 developed by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy, for the treatment of patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ). This collaboration includes two global phase I/II open-label, multi-center studies, one to be held in the U.S. an…

- Creation of new company combines strengths of three leading value-based care specialists- Execution on strategic expansion along the renal care continuum significantly expands Fresenius Medical Care's total addressable market in the U.S. from around $50 billion to around $170 billion- Establishing independent and integrated value-based care offering in-line with FME25 plan of refining and further growing future Care Delivery segment in the U.S. Fresenius Medical Care, the world's leading provider of products and services for individuals with kidney diseases, announced today it has entered into a binding agreement to create an independent new company that combines Fresenius Health Partners, the value-based care division of Fresenius Medical Care North America, with InterWell Health, the l…

Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer Paris, March 16, 2022. Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has one ADC in development. John Reed, M.D., Ph.D.Global Head of Research and Development, Sanofi“This collaboration will enable the synergistic combination of molecules and platforms to produce candidate medicines with th…

NORTH CHICAGO, Ill., March 15, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19. "Constant change is something we've experienced throughout the COVID-19 pandemic, with the emergence of many new variants and the evolving needs of treatment options to combat more contagious, aggressive and severe strains of the virus," said Tom Hudson, M.D., senior vice president, R&D, chief scientific officer, AbbVie. "We are committed to bringing differentiated, next generation oral antiviral treatments to patients and ensuring broad access to address the diverse treatment needs around the world." Th…

Investment will accelerate the overall Sarclisa® development program Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa® (isatuximab) PARIS, March 15, 2022. Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM). If successful, BXLS will be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022. For the…

NORTH CHICAGO, Ill. and BUDAPEST, Hungary, March 11, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR® / REAGILA®). "In collaboration with Richter, we will continue to build on our research that seeks to provide additional insights into our understanding of caripra…

Digital Diagnostics and Baxter International Inc. announced a long-term strategic partnership to help front line care providers deliver high-quality care and improve care outcomes. The partnership includes plans to offer Digital Diagnostics’ industry-leading IDx-DR® autonomous AI software as a diagnostic service combined with the Welch Allyn® RetinaVue® 700 Imager.  Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (including diabetic macular edema) at the point-of-care. Only 15% of people with diabetes receive the recommended annual diabetic eye exam.1,2 Access to effective diagnostic services is an obstacle, especially in rural or underserved areas. It leaves many with undiagnosed and untreated levels of disease, and a highe…

Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion and strengthening of its service capabilities by acquiring SFL (Solutions for Life Sciences). With headquarters in Basel, Switzerland and several European affiliates, SFL brings unique capabilities and a highly credentialed team to support a growing number of biotech, pharmaceutical and medtech companies. Led by Founder and CEO Shayesteh Fürst-Ladani, the SFL team has longstanding experience in providing strategic advice and operational support for all stages of product development, with in-house…

Pharma and biotech customers distinguish excellence in capabilities, expertise, quality, compatibility, reliability and service Waltham, Mass. (March 3, 2022) – For the third consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing leadership in all six categories of the 11th Annual CMO Leadership awards. The annual honors, presented by Life Science Leader and Outsourced Pharma, spotlight excellence in Capabilities, Expertise, Quality, Compatibility, Reliability and Service. The customers evaluated 86 companies across 23 performance metrics. "Patients worldwide need treatments sooner than ever so we need to exceed our customers’ expectations every day,” said Mike Shafer, senior vice president and president, pharma servi…

WILMINGTON, N.C. (March 2, 2022) –Thermo Fisher Scientific’s PPD clinical research business has been named a winner in Training magazine’s 2022 Training APEX Awards, recognizing its robust enterprise learning programs designed to grow employees’ skills and drive customers’ success. As part of Thermo Fisher’s commitment to talent development, the PPD clinical research business designs, develops and deploys a wide range of employee learning and performance programs, providing ongoing training and development that engages employees for optimal performance, leverages technology, develops staff and measures outcomes. “We are honored to win this award for the 11th consecutive year from the highly regarded team at Training magazine,” said Jay Dixon, senior vice president, quality and enterprise l…

- Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies- Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential tre…

Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine The leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today announce partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.  “This platform will play an important part of Boehringer Ingelheim’s broader strategy to capture translational disease insights from large external healthcare biobanks and u…